SELECTA
10.11.2021 18:15:12 CET | Business Wire | Press release
Selecta, Europe’s leading route-based self-service retailer, announces its results for the three months ended 30 September 2021:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211110006099/en/
Q3 Performance Summary1
Sales1 of €260.8 million, an increase of 4.1% compared to the Group’s sales for Q3 2020 and also higher than sales for Q2 2021, with a with a gradual pick up intra-quarter reaching 76.3% of 2019 levels in Q3-21.
Sales continue to be impacted by the pandemic mostly due to work-from-home policies, although we saw a gradual recovery of activity throughout the summer. In the quarter, the toughest conditions were seen in Denmark and Norway, while the most Covid-19 impacted countries including Italy, UK, Spain and France have demonstrated good momentum as market conditions improvement and Austria, Netherlands and Switzerland are now close to 2019 levels. The Private channel showed some progress in sales per machine per day (“SMD”) performance with the Manufacturing and Logistics segments showing resilence, offset by the Service and Administration segments which continues to be negatively impacted by work-from-home policies. The Semi-public channel SMD showed better performance driven by the Education and Healthcare segments and the Public channel remains the closest to pre-pandemic SMD levels driven by the Petrol and Railway segments.
Adjusted EBITDA3,4 of €52.5 million, significantly ahead of last year, driven by structural cost-savings taking hold as our initial rightsizing actions are now close to completion. In turn, EBITDA margin was 20.1%, up 8.2 percentage points compared to last year.
Reported EBITDA4 of €44.3 million and free cash flow (“FCF”) of €20.4 million continue to be impacted, as expected, by the one-off costs related to the rightsizing of the organization.
Liquidity headroom5 of €164.8 million, reflects a strong liquidity position which was maintained due to strong free cash flow generation despite the interest payment in July.
Joe Plumeri, Executive Chairman, said:
“We continue to make excellent progress in the execution our ONE Selecta transformation vision. Our focus on best-in-class sales and service continues through targeted training and development programs that will set us apart from the rest. Ongoing investments in technology continue, with our new CRM system now successfully integrated across our 16 countries. This will further drive the successful ONE Selecta end-to-end sales process which benefits not only our sales teams, but our clients.”
Christian Schmitz, Group Chief Executive Officer, said:
“Selecta remains superbly positioned to meet the needs of the post COVID-19 world. Although extended work from home policies impacted the Private sector over the last quarter, we continue to deliver innovative solutions to our clients that perfectly meet the needs of the new hybrid working model. We are excited to be so well positioned as the European partner of choice for employers seeking innovative and scalable food options combined with globally recognized premium coffee brands. The rightsizing of the organization is close to completion, and we now look towards investing in our people to support future growth.”
- ENDS -
About Selecta Group
Headquartered in Switzerland since 1957, Selecta Group is Europe’s leading route-based, self-service provider offering great quality coffee and innovative convenience food solutions in the workplace and public spaces. Every day we serve premium coffee and beverages, snacks and fresh meals to more than 10 million people in 16 countries across Europe through vending services and solutions companies in all business segments. With an annual turnover of €1.0 billion, we owe our success to our ca. 7,100 highly skilled, dedicated and passionate Selecta employees who are committed to creating millions of moments of joy for our clients and their consumers every day. Sustainability is an integral part of the way we do business, focused on the key areas in which we can make a positive difference. For more information, please visit www.selecta.com
Cautionary Statement
We are providing this information voluntarily, and the material contained in this announcement is presented solely for information purposes and is not to be construed as providing investment advice. As such, it has no regard to the specific investment objectives, financial situation or particular needs of any recipient. No representation or warranty, either express or implied, is made as to, and no reliance should be placed on, the fairness, completeness, accuracy, correctness or reliability of the information contained herein or the assumptions upon which the information is based. It should not be regarded by recipients as a substitute for the exercise of their own judgment. Neither Selecta, nor any of its directors, officers, employees, affiliates, direct or indirect shareholders, advisors or agents accepts any liability for any direct, indirect, consequential or other loss or damage suffered by any person as a result of relying on all or any part of this announcement and any liability is expressly disclaimed.
Forward-Looking Statements
This press release includes “forward-looking statements” that involve risks, uncertainties and other factors, many of which are outside of Selecta’s control and could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning Selecta’s plans, objectives, goals, future events, performance or other information that is not historical information. All statements other than statements of historical fact referred to in this press release are forward-looking statements. Forward-looking statements give Selecta’s or the Group’s current expectations and projections relating to its financial condition, results of operations, plans, objectives, future performance and business. These statements may include, without limitation, any statements preceded by, followed by or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Such forward-looking statements, as well as those included in any other material, are subject to known and unknown risks, uncertainties and assumptions about Selecta, its present and future business strategies, trends in its operating industry and the environment in which it will operate in the future, future capital expenditure and acquisitions. In light of these risks, uncertainties and assumptions, the events in the forward-looking statements may not occur or Selecta’s or the Group’s actual results, performance or achievements might be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. None of Selecta, its affiliates or their respective directors, officers, employees, agents or advisers undertake to publicly update or revise forward- looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
1
At actual exchange rates. There is no material difference from constant currency rates
2
Sales: Revenue after payment of vending fees
3
Adjusted EBITDA: Earnings before Interest, Tax, Depreciation and Amortization and prior to one-off items (external and internal costs which are not related to the on-going business)
4
2021 numbers include the effects of IFRS 16, which was adopted from 1 Jan 2020
5
Cash at Bank of €76.0 million plus €88.8 million available RCF
Note: September 2019 figures have been adjusted for one-time impacts
View source version on businesswire.com: https://www.businesswire.com/news/home/20211110006099/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
